Navigation Links
Echo Therapeutics to Present at the New York Society of Security Analysts' 13th Annual Biotech and Specialty Pharmaceuticals Conference
Date:11/24/2009

FRANKLIN, Mass., Nov. 24 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that Patrick T. Mooney, M.D., Chairman and Chief Executive Officer, will present at the 13th Annual Biotech and Specialty Pharmaceuticals Conference, sponsored by the New York Society of Securities Analysts, at 2:05 on December 1, 2009. The conference is being held at the offices of the New York Society of Security Analysts, 1177 Avenue of the Americas, New York, NY.

For further information about this conference, please contact Derly Vargas at 646-871-3405 or dvargas@nyssa.org.

About Echo Therapeutics

Echo Therapeutics is focused on medical devices and specialty pharmaceuticals. Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System for transdermal drug delivery of a wide range of novel topical reformulations of widely-used, FDA-approved products.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the efficacy of Echo's Symphony tCGM System an
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
2. Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis
3. Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal
4. Echo Therapeutics Announces Positive Results of a Clinical Study Testing Symphony(TM) tCGM System in Patients with Type 1 and Type 2 Diabetes
5. Mersana Therapeutics Provides Clinical Update from Ongoing Phase 1 Study of XMT-1001 in Patients with Advanced Solid Tumors
6. Oxygen Biotherapeutics, Inc. Begins Shipping Cosmetic Product to Customers
7. Paloma Pharmaceuticals Presents at the AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics
8. Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
9. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
10. Tobira Therapeutics Announces Presentation of TBR-652 Data at European AIDS Conference
11. Reportlinker Adds Pain Therapeutics 2005: Market Dynamics and Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... , July 27, 2015 Bloomage BioTechnology Corporation ... a strategic cooperation with the South Korean BioTech Company ... joint venture Medybloom to develop and promote Type A ... . Medytox, the Botulinum Toxin ... is also the fourth company in the world successfully ...
(Date:7/27/2015)... , July 27, 2015 Varian Medical Systems ... National Health Service to equip and service two new national ... with the Varian ProBeam ® proton therapy system. Earlier ... preferred supplier for two three-room NHS centers to be constructed ... . Varian expects to book the equipment portion of ...
(Date:7/27/2015)... 2015 EMD Millipore , the ... of Darmstadt, Germany , today ... pegylation services to customers developing protein-based therapeutics and ... collaboration includes feasibility studies, process and analytical development, ... for pilot and subsequent commercial scale. ...
Breaking Medicine Technology:Bloomage (00963.HK) and Medytox Inc. set up a Joint Venture To Jointly Develop Botulinum Toxin Market in China 2Bloomage (00963.HK) and Medytox Inc. set up a Joint Venture To Jointly Develop Botulinum Toxin Market in China 3Varian Signs Contracts to Equip Two National Proton Therapy Centers in England 2Varian Signs Contracts to Equip Two National Proton Therapy Centers in England 3Varian Signs Contracts to Equip Two National Proton Therapy Centers in England 4EMD Millipore Adds Protein Pegylation to Portfolio of Services for Biopharmaceutical Industry through Collaboration with celares GmbH 2EMD Millipore Adds Protein Pegylation to Portfolio of Services for Biopharmaceutical Industry through Collaboration with celares GmbH 3
... (Nasdaq: PDEX ) today announced its financial results for ... addition, Pro-Dex announced that its existing credit agreement with Wells ... hired, a product development agreement was signed with a new ... developed product. , Sales for the first quarter ended September ...
... Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) ... company, today announced they have entered into an exclusive ... Australia and New Zealand. An intravenous formulation of ibuprofen, ... the hospital setting. Cumberland Pharmaceuticals received U.S. Food and ...
Cached Medicine Technology:PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 2PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 3PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 4PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 5PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 6PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 7PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 8PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 9PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 10Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand 2Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand 3Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand 4Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand 5
(Date:7/27/2015)... ... July 27, 2015 , ... A Harris County jury awarded a ... against Canadian stock promoter Robert Kubbernus based on findings of fraud and violations of ... accepted by the court in Cause No. 2010-09675; Jo Ann Schermerhorn, et al v. ...
(Date:7/27/2015)... , ... July 27, 2015 , ... Throughout its 20 ... premier doctors and medical providers working on a lien basis. As the personal ... wide range of providers from chiropractors, to orthopedists, to pain management physicians, to psychologists ...
(Date:7/27/2015)... , ... July 27, 2015 , ... According to an ... rate of hepatitis C has increased in Tennessee stemming from intravenous drug use. Intravenous ... medical professionals at risk for contracting communicable diseases including Hepatitis B and C and ...
(Date:7/27/2015)... ... ... SupplyLogic, a marketing execution partner based in metro New York and Chicago has ... Founder and CEO Kevin Sherlock discusses the value in supply chain visibility by quoting ... it the closer you get to the ocean, the more seafood costs?’ Those of ...
(Date:7/27/2015)... ... July 27, 2015 , ... Continuing their ongoing ... serving the greater San Antonio area, is launching a joint charity effort with ... Big Brother Big Sister Organization of South Texas is committed to serving underprivileged ...
Breaking Medicine News(10 mins):Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 2Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 3Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 4Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 5Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 6Health News:Doctors on Liens Adds Highly Respected Physical Therapy Office in Los Angeles 2Health News:Tennessee Sees an Increase in Hepatitis C Infections from Intravenous Heroin Use 2Health News:Tennessee Sees an Increase in Hepatitis C Infections from Intravenous Heroin Use 3Health News:SupplyLogic Releases First Executive Blog on Supply Chain Management Issues 2Health News:Shacklett Insurance Team Joins Local Chapter of Big Brother Big Sister Organization to Initiate Joint Charity Effort to Benefit Children in San Antonio 2Health News:Shacklett Insurance Team Joins Local Chapter of Big Brother Big Sister Organization to Initiate Joint Charity Effort to Benefit Children in San Antonio 3
... Health ChoicesMIDLAND, Mich., Feb. 11 With Earth ... to go green. By implementing Health Enhancement ... www.HealthEnhancementSystems.com ), Green Planet Wellness ... ), participants learn small steps that can add ...
... Feb. 11 Doctors with Plastic Surgery Services ... in the area to offer LATISSE(TM), the new ... growing them darker, fuller and longer. LATISSE,s ... such as BOTOX(R) and Juvederm(TM). The active ingredient ...
... VIEJO, Calif., Feb. 11 Valeant Pharmaceuticals International (NYSE: ... host a conference call on Tuesday, February 24, 2009 ... results for the 2008 fourth quarter and year.The dial-in ... confirmation code 83660030. International callers should ...
... to start of chronic lymphocytic leukemia , , WEDNESDAY, ... appear in the blood years before a person is ... , They added that this finding may help improve ... stages of leukemia, and how the disease progresses. , ...
... with atrial fibrillation , , WEDNESDAY, Feb. 11 (HealthDay News) ... produced promising results in its latest trial. , The ... affects an estimated 2.2 million Americans. The upper chambers ... the formation of blood clots that can block a ...
... 11 Symmetry Medical Inc. (NYSE: SMA ), ... device industry and other medical markets, announced today that it ... for the period ending January 3, 2009 before the market ... an accompanying conference call at 9:00 a.m. ET on Tuesday, ...
Cached Medicine News:Health News:Green Planet Wellness Helps Employers Have Big Environmental Impact 2Health News:Long and Lovely Lashes by LATISSE(TM) Now Available Through Plastic Surgery Services of Fredericksburg 2Health News:Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009 2Health News:Signs of Leukemia Show Up Years Before Diagnosis 2Health News:New Drug Shows Promise Against Heartbeat Abnormality 2Health News:New Drug Shows Promise Against Heartbeat Abnormality 3Health News:Symmetry Medical to Report Fourth Quarter and Full Year 2008 Financial Results on February 24, 2009 2
... Endoscopic CycloPhotocoagulation (ECP) is a surgical approach ... and visualized laser application. The ciliary body ... the surgeon, from the anterior or posterior ... The target tissues are easily and accurately ...
... Craftsmanship have produced the finest ... Ocutek® now makes them available ... the coveted Meisterbrief certificate, which ... qualified to become Ocutek instrument ...
... surgical approach to glaucoma management that employs ... ciliary body (which produces aqueous humour) is ... or posterior segment, through the endoscope in ... and accurately identified utilizing endoscopy. This allows ...
... Endoscopic CycloPhotocoagulation (ECP) is a surgical ... endoscopy and visualized laser application. The ciliary ... by the surgeon, from the anterior or ... time. The target tissues are easily and ...
Medicine Products: